Brief: Cingulate Announces Successful Transfer Of Ctx-1301 (Dexmethylphenidate) Proprietary Ptr™ Manufacturing Processes To Societal Cdmo

Cingulate

03/05/2023 12:24

Cingulate Inc  CING.O :
    * CINGULATE ANNOUNCES SUCCESSFUL TRANSFER OF CTX-1301
(DEXMETHYLPHENIDATE) PROPRIETARY PTR™ MANUFACTURING PROCESSES TO
SOCIETAL CDMO
    * CINGULATE INC- ASSUMING POSITIVE CLINICAL RESULTS FROM
PHASE 3
TRIALS, PLANS TO SUBMIT NDA FOR CTX-1301 IN MID-2024 UNDER
SECTION 505(B)(2) PATHWAY
    * CINGULATE INC- PLANS TO COMMENCE ITS PIVOTAL PHASE 3
FIXED-DOSE
PEDIATRIC AND ADOLESCENT STUDY FOR CTX-1301 IN MID-2023

Source text for Eikon:  ID:nGNX1G1pkY 
Further company coverage:  CING.O